• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>RSC Advances >Tandem microfluidic chip isolation of prostate and breast cancer cells from simulated liquid biopsies using CD71 as an affinity ligand
【24h】

Tandem microfluidic chip isolation of prostate and breast cancer cells from simulated liquid biopsies using CD71 as an affinity ligand

机译：使用CD71作为亲和配体，将模拟液体活组织检查分离前列腺和乳腺癌细胞的串联微流体芯片分离

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The use of blood as a liquid biopsy provides a minimally invasive and less traumatic approach for initial cancer screens as well as patient monitoring. However, current clinical protocols require a priori knowledge of cancer type for liquid biopsy analyses. Previously, we proposed the use of the human transferrin 1 receptor protein (CD71) as a universal capture target for cancer cells analyses. In this study we have attempted to identify the lowest limit of detection for circulating tumor cells of prostate (PC-3) and breast cancers (MDA-MB-231) using CD71. We used a novel high-throughput herringbone chip design which could extract PC-3 cells at 34 ± 5% purity and MDA-MB-231 cells at 43 ± 35% purity when spiked to lysed blood at 0.1%. MDA-MB-231 cell spiked samples showed higher standard deviation, but the system captured 55 ± 16 cells, which is a sufficient number of cells for subsequent analyses. Further, this herringbone chip design has been shown to be compatible with an erythrocyte lysis chip we have described in previous studies. This circuit was capable of capturing 510 ± 120 cells with a purity of 82 ± 14% using <7 μL of a whole blood sample spiked with 10% MDA-MB-231 cells. Using an erythrocyte lysis circuit eliminates the need for human intervention for target cell enrichment, thereby reducing cell loss and sample contamination. We have shown that, when used with the high-throughput herringbone chip CD71 has the capacity to sensitively detect rare target cells for routine low-cost cancer screens.
机译：血液作为液体活检的使用提供了初始癌症屏幕的微创和更少的创伤方法以及患者监测。然而，目前的临床协议需要先验的癌症类型的癌症分析。以前，我们提出使用人转移素1受体蛋白（CD71）作为癌细胞分析的通用捕获靶标。在这项研究中，我们试图使用CD71识别前列腺癌（PC-3）和乳腺癌（MDA-MB-231）的循环肿瘤细胞的最低限度。我们使用了一种新型的高通量人字形芯片设计，当掺入0.1％时，在43±35％的纯度下，可以在34±5％纯度和MDA-MB-231细胞中提取PC-3细胞。 MDA-MB-231细胞掺入样品显示出更高的标准偏差，但系统捕获了55±16个细胞，其是随后分析的足够数量的细胞。此外，这种人字形芯片设计已被证明与我们在先前研究中描述的红细胞裂解芯片相容。使用掺入10％MDA-MB-231细胞的7μL全血样，该电路能够捕获510±120个细胞，纯度为82±14％。使用红细胞裂解电路消除了人类侵害靶细胞富集的需要，从而减少细胞损失和样品污染。我们已经表明，与高通量人字形芯片一起使用时，CD71具有敏感地检测罕见靶细胞的能力，用于常规低成本癌症屏幕。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号